Beta-carbolines useful for treating inflammatory disease
申请人:Hepperle E. Michael
公开号:US20050239781A1
公开(公告)日:2005-10-27
This invention provides beta-carboline compounds of formula III-A-aa:
wherein Q, G, R
1
, R
2
, R
3
, and R
6b
are as described in the specification. The compounds are useful for treating diseases such as inflammatory diseases and cancer.
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
[EN] IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE UTILISABLES EN TANT QUE MODULATEURS DE L'ACTIVITÉ TNF
申请人:UCB PHARMA SA
公开号:WO2014009295A1
公开(公告)日:2014-01-16
A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
The present invention encompasses compounds of general formula (1)
wherein
R
1
to R
3
are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
本发明涵盖了一般式(1)的化合物
其中
R
1
至 R
3
如权利要求书中所定义,适用于治疗以细胞过度或异常增殖为特征的疾病,并用于制备具有上述特性的药物组合物。
[EN] BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE<br/>[FR] BETA-CARBOLINES UTILES POUR TRAITER UNE MALADIE INFLAMMATOIRE
申请人:MILLENNIUM PHARM INC
公开号:WO2004092167A1
公开(公告)日:2004-10-28
This invention provides beta-carboline compounds of formula (I) wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2 mediated diseases such as inflammatory diseases and cancer.